Please assess the completion status of the following clinical trial:

Trial Title: Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female age between 2 and 65 years (inclusive)~* Parasites visualized on splenic aspiration~* Signs and symptoms compatible with visceral leishmaniasis (e.g. fever, splenomegaly, anaemia, weight loss, leucopenia, thrombocytopenia)~* Confirmed diagnosis of VL by visualization of parasites on splenic/bone marrow aspirate~* Fever for at least 2 weeks~* Written informed consent from the patient/or from parent or guardian if under 18 years old~Exclusion Criteria:~* Hemoglobin \< 6 g/dl~* White blood cell count \< 1000/mm3~* Platelets \<50,000~* Prothrombin time \> 5 sec above control~* ASAT \> 3 times the upper limit of normal~* Serum creatinine or BUN \> 1.5 times the upper limit of normal~* Malaria~* Tuberculosis~* HIV positive serology~* Lactation, pregnancy~* Refusing contraception method during treatment period plus 3 months~* Any medical condition(s) that upon judgment of physician may affect the safety of the patient when treated with study drugs~* Any concomitant drug that is nephrotoxic

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)

Based on this trial design, predict the completion outcome and termination type (if applicable).